KR20180121539A - 급성 신부전의 치료에 사용하기 위한 암브리센탄 - Google Patents
급성 신부전의 치료에 사용하기 위한 암브리센탄 Download PDFInfo
- Publication number
- KR20180121539A KR20180121539A KR1020187026495A KR20187026495A KR20180121539A KR 20180121539 A KR20180121539 A KR 20180121539A KR 1020187026495 A KR1020187026495 A KR 1020187026495A KR 20187026495 A KR20187026495 A KR 20187026495A KR 20180121539 A KR20180121539 A KR 20180121539A
- Authority
- KR
- South Korea
- Prior art keywords
- subject
- administered
- rti
- ambriscentan
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310221P | 2016-03-18 | 2016-03-18 | |
| US62/310,221 | 2016-03-18 | ||
| EP16166046.9A EP3235496A1 (en) | 2016-04-19 | 2016-04-19 | Treatment of acute renal failure |
| EP16166046.9 | 2016-04-19 | ||
| US201662437949P | 2016-12-22 | 2016-12-22 | |
| US62/437,949 | 2016-12-22 | ||
| PCT/EP2017/056476 WO2017158199A1 (en) | 2016-03-18 | 2017-03-20 | Ambrisentan for use in the treatment of acute renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180121539A true KR20180121539A (ko) | 2018-11-07 |
Family
ID=55808404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187026495A Ceased KR20180121539A (ko) | 2016-03-18 | 2017-03-20 | 급성 신부전의 치료에 사용하기 위한 암브리센탄 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10870021B2 (https=) |
| EP (3) | EP3235496A1 (https=) |
| JP (1) | JP7237362B2 (https=) |
| KR (1) | KR20180121539A (https=) |
| CN (1) | CN109069443A (https=) |
| AU (1) | AU2017235618B2 (https=) |
| BR (1) | BR112018067602A2 (https=) |
| CA (1) | CA3015432A1 (https=) |
| CL (1) | CL2018002638A1 (https=) |
| DK (1) | DK3429566T3 (https=) |
| ES (2) | ES2966638T3 (https=) |
| HK (1) | HK1259616A1 (https=) |
| IL (1) | IL261457B (https=) |
| MX (1) | MX374534B (https=) |
| SG (1) | SG11201808009SA (https=) |
| WO (1) | WO2017158199A1 (https=) |
| ZA (1) | ZA201805562B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3639827A1 (en) * | 2018-10-19 | 2020-04-22 | Noorik Biopharmaceuticals AG | Use of ambrisentan for the treatment of portal hypertension and cirrhosis |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| WO2021219691A1 (en) * | 2020-04-29 | 2021-11-04 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| CA2695259C (en) * | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| MX2014010209A (es) | 2012-02-29 | 2014-11-21 | Toray Industries | Agente inhibidor para acumulacion de fluido de la cavidad corporal. |
| CN105324395A (zh) * | 2013-03-08 | 2016-02-10 | 艾伯维公司 | 治疗急性肾损伤的方法 |
| EP2988770A4 (en) | 2013-04-26 | 2016-12-14 | La Jolla Pharma Co | COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES |
| WO2015069839A1 (en) * | 2013-11-06 | 2015-05-14 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
-
2016
- 2016-04-19 EP EP16166046.9A patent/EP3235496A1/en not_active Withdrawn
-
2017
- 2017-03-20 EP EP17711211.7A patent/EP3429566B1/en active Active
- 2017-03-20 MX MX2018011222A patent/MX374534B/es active IP Right Grant
- 2017-03-20 WO PCT/EP2017/056476 patent/WO2017158199A1/en not_active Ceased
- 2017-03-20 BR BR112018067602A patent/BR112018067602A2/pt not_active Application Discontinuation
- 2017-03-20 ES ES20175547T patent/ES2966638T3/es active Active
- 2017-03-20 ES ES17711211T patent/ES2856960T3/es active Active
- 2017-03-20 AU AU2017235618A patent/AU2017235618B2/en active Active
- 2017-03-20 SG SG11201808009SA patent/SG11201808009SA/en unknown
- 2017-03-20 KR KR1020187026495A patent/KR20180121539A/ko not_active Ceased
- 2017-03-20 CN CN201780017563.3A patent/CN109069443A/zh active Pending
- 2017-03-20 CA CA3015432A patent/CA3015432A1/en active Pending
- 2017-03-20 US US16/084,340 patent/US10870021B2/en active Active
- 2017-03-20 JP JP2019500021A patent/JP7237362B2/ja active Active
- 2017-03-20 DK DK17711211.7T patent/DK3429566T3/da active
- 2017-03-20 EP EP20175547.7A patent/EP3878439B1/en active Active
- 2017-03-20 HK HK19101803.4A patent/HK1259616A1/zh unknown
-
2018
- 2018-08-21 ZA ZA2018/05562A patent/ZA201805562B/en unknown
- 2018-08-29 IL IL261457A patent/IL261457B/en unknown
- 2018-09-14 CL CL2018002638A patent/CL2018002638A1/es unknown
-
2020
- 2020-10-07 US US17/065,097 patent/US11642307B2/en active Active
-
2023
- 2023-03-31 US US18/129,516 patent/US20230233454A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3429566T3 (da) | 2021-03-29 |
| EP3878439A1 (en) | 2021-09-15 |
| EP3878439B1 (en) | 2023-10-04 |
| ES2966638T3 (es) | 2024-04-23 |
| EP3235496A1 (en) | 2017-10-25 |
| IL261457B (en) | 2021-09-30 |
| NZ746140A (en) | 2022-03-25 |
| ZA201805562B (en) | 2019-06-26 |
| EP3429566A1 (en) | 2019-01-23 |
| EP3429566B1 (en) | 2021-01-27 |
| SG11201808009SA (en) | 2018-10-30 |
| US11642307B2 (en) | 2023-05-09 |
| HK1259616A1 (zh) | 2019-12-06 |
| AU2017235618B2 (en) | 2021-02-25 |
| JP7237362B2 (ja) | 2023-03-13 |
| CA3015432A1 (en) | 2017-09-21 |
| MX374534B (es) | 2025-03-06 |
| IL261457A (en) | 2018-10-31 |
| JP2019515942A (ja) | 2019-06-13 |
| WO2017158199A1 (en) | 2017-09-21 |
| US20210046332A1 (en) | 2021-02-18 |
| MX2018011222A (es) | 2019-01-10 |
| ES2856960T3 (es) | 2021-09-28 |
| BR112018067602A2 (pt) | 2019-01-08 |
| US10870021B2 (en) | 2020-12-22 |
| CN109069443A (zh) | 2018-12-21 |
| CL2018002638A1 (es) | 2019-01-18 |
| AU2017235618A1 (en) | 2018-09-27 |
| US20230233454A1 (en) | 2023-07-27 |
| US20190083820A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230233454A1 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| US20260000767A1 (en) | Formulations of bendamustine | |
| TWI900606B (zh) | 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合 | |
| Corrigan et al. | PAH extraction and estimation of plasma flow in human postischemic acute renal failure | |
| Clark‐Price et al. | Physiology, pathophysiology, and anesthetic management of patients with renal disease | |
| AU2014346682B2 (en) | Novel formulations | |
| Fernández-Varo et al. | Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites | |
| KR20220080181A (ko) | 신독소-유도된 신장 손상의 치료 및 예방 | |
| Bayram et al. | The effects of intraoperative infusion of dexmedetomidine on early renal function after percutaneous nephrolithotomy | |
| Wilson et al. | Oliguria: a sign of renal success or impending renal failure? | |
| CA2848210A1 (en) | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients | |
| Cousins et al. | Anaesthesia, surgery and renal function: immediate and delayed effects | |
| NZ786075A (en) | Ambrisentan for use in the treatment of acute renal failure | |
| NZ746140B2 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| KR20230107866A (ko) | Btk 억제제를 사용한 전신성 홍반성 루푸스의 치료 방법 | |
| JP2022518143A (ja) | ビタミンｅならびにがん治療用組成物および方法 | |
| WO2020094251A2 (en) | Treatment of portal hypertension and cirrhosis | |
| US20260027094A1 (en) | Use of pyridone derivative | |
| Saupe et al. | Effects of AT1 receptor block begun late in life on normal cardiac aging in rats | |
| US20230241218A1 (en) | Formulations of bendamustine | |
| US9682071B2 (en) | Methods of improving microvascular integrity | |
| Bland-van den Berg | Investigations into the hemodynamic and metabolic effects of fructose 1, 6 diphosphate and prostacyclin in hypovolemic shock | |
| Proteinuria | Renal Transplant Dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180913 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200117 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210330 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210827 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210330 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |